Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Patients with atrial fibrillation (AF) after an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) with multiple comorbidities are at increased risk for bleeding and ischemic events.
Objectives: This post-hoc analysis of AUGUSTUS describes the safety and efficacy of antithrombotic regimens in patients with multimorbidity.
Methods: AUGUSTUS was a 2 × 2 factorial, randomized controlled trial evaluating the safety of apixaban vs vitamin K antagonists (VKA) (open-label) and aspirin vs placebo (double-blind) in patients with AF and ACS and/or PCI treated with a P2Y inhibitor. Patients were categorized as having no multimorbidity (0-2 comorbidities), moderate multimorbidity (3-4 comorbidities), or high multimorbidity (≥5 comorbidities). The associations between multimorbidity and clinical outcomes and interactions with antithrombotic regimens were tested.
Results: Of 4,493 patients (97.4%) with available comorbidity data, 1,897 (42.2%) had no multimorbidity, 2,110 (47%) had moderate, and 486 (10.8%) had high multimorbidity. Patients with moderate (HR: 1.23; 95% CI: 1.02-1.47) and high (HR: 1.98; 95% CI: 1.55-2.54) multimorbidity had higher rates of International Society on Thrombosis and Haemostasis (ISTH) major or clinically relevant nonmajor (CRNM) bleeding compared to patients with no multimorbidity. No significant interaction between multimorbidity and apixaban vs vitamin K antagonists was observed for ISTH major bleeding/CRNM ( = 0.415), death or hospitalization ( = 0.092), or death or ischemic event ( = 0.299). Similarly, no significant interaction between multimorbidity and aspirin vs placebo was seen for ISTH major bleeding/CRNM ( = 0.261), death or hospitalization ( = 0.646), or death or ischemic event ( = 0.608).
Conclusions: Our findings support the standard use of apixaban plus a P2Y inhibitor in patients with AF and ACS/PCI, irrespective of the presence of multimorbidity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530834 | PMC |
| http://dx.doi.org/10.1016/j.jacadv.2024.101335 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: The International Society of Thrombosis and Hemostasis (ISTH) guidelines suggest a three-step evaluation for the detection of lupus anticoagulant (LA), including screening, mixing, and confirmation. According to the guidelines, the LA assay based on activated partial thromboplastin time (APTT) should include an initial screening step followed by a confirmatory step that uses a higher concentration of phospholipids in either bilayer or hexagonal form. For the activator, the guidelines recommend using silica, though ellagic acid is also an option.
View Article and Find Full Text PDFIntroducing the New Definition and Diagnostic Criteria of Disseminated Intravascular Coagulation Released by the International Society on Thrombosis and Haemostasis in 2025.
Semin Thromb Hemost
August 2025
Department of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, North Carolina.
In 2025, the International Society on Thrombosis and Haemostasis (ISTH) released updated definitions and diagnostic criteria for disseminated intravascular coagulation (DIC), reflecting advances in understanding its pathophysiology. DIC is now defined as an acquired, life-threatening condition involving systemic coagulation activation, impaired fibrinolysis, and endothelial injury. The revised framework emphasizes the condition's dynamic nature, progressing from preclinical abnormalities to overt clinical manifestations such as bleeding and organ dysfunction.
View Article and Find Full Text PDFVenous thromboembolism prophylaxis practices in hematology/oncology patients admitted to neurological intensive care units.
Front Cardiovasc Med
July 2025
Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Objective: Venous thromboembolism (VTE) presents a significant challenge for neurocritically ill patients with cancer due to the combined risks of thrombosis and bleeding. This study aimed to describe VTE prophylaxis practices among this high-risk population.
Methods: This is a retrospective cohort study at a tertiary teaching hospital.
Artificial intelligence in Nigerian oncology practice: A qualitative exploration of oncologists' perspectives.
J Cancer Policy
September 2025
Division of Sustainable Development, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.
Background: Artificial intelligence (AI) offers potential solutions to address critical challenges in oncology practice, particularly in resource-constrained settings like Nigeria. However, successful implementation requires understanding healthcare providers' perspectives, which remain largely unexplored in the Nigerian context.
Aim: To explore Nigerian oncologists' perspectives on AI applications in oncology practice, identifying knowledge levels, perceived benefits, implementation barriers, and priority areas for AI integration.
Evaluating the Safety and Efficacy of Asundexian in Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Clin Appl Thromb Hemost
July 2025
School of Medicine, The Maldives National University, Malé, Maldives.
BackgroundThromboembolic events remain a major cause of morbidity and mortality in cardiovascular diseases, particularly myocardial infarction, atrial fibrillation (AF), and ischemic stroke. While standard anticoagulants reduce these events, their use is limited by bleeding risks. Asundexian, a Factor XIa inhibitor, has emerged as a potential agent to prevent thrombosis while preserving hemostasis.
View Article and Find Full Text PDF